Latigo Biotherapeutics (NASDAQ:LTGO) reported quarterly earnings results on November 05, 2026 that exceeded analyst expectations.
At publication ·
Latigo Biotherapeutics (NASDAQ:LTGO) · earnings beat
At a glance
Latigo Biotherapeutics (NASDAQ:LTGO) reported quarterly earnings results on November 05, 2026 that exceeded analyst expectations.
The company reported earnings per share of $-0.55, beating the consensus estimate of $-0.67 by $0.12 per share. Revenue came in at , meeting the estimate of .
Latigo Biotherapeutics's stock moved following the earnings release.
Latigo Biotherapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 18% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Latigo Biotherapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
| Quarter | EPS Actual | EPS Est. | Surprise |
|---|---|---|---|
| Q3 (Nov 2026) | $-0.55 | $-0.67 | +17.9% |
| Q2 (Sep 2026) | $-27.59 | $-0.46 | -5897.8% |
Related Tools: Earnings Calendar | View LTGO Stock Page
Check the latest earnings dates on our LTGO earnings page or the Earnings Calendar.
See the full Q3 results including EPS actual vs estimate on our LTGO earnings page.
Current market data
NASDAQ · LTGO
